Poster Psoriasis Conclusions: These results from both in vivo and ex vivo testing demonstrated that long-term treatment with UST doesnot compromise the immune response to T-cell dependent or T-cell independent vaccines in patients with moderate to severe psoriasis. 84
Poster Psoriasis P 34 Long-term safety and efficacy of ustekinumab in patients with psoriasis inadequately responding to methotrexate: Week 52 TRANSIT results C. Paul 1 L. Puig 2 T. Luger 3 J. Lambert 4 S. Chimenti 5 G. Girolomoni 6 J.-F. Nicolas 7 K. Kragballe 8 E. Rizova 9 S. Mistry 10 P. Bergmans 11 J. Barker 12 K. Reich 13 1 Larrey Hospital, Paul Sabatier University, Toulouse, France 2 Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain 3 University of Munster, Munster, Germany 4 Ghent University Hospital, Ghent, Belgium 5 University of Rome, Rome, Italy 6 University of Verona, Verona, Italy 7 University of Lyon, Lyon, France 8 Arhus University, Arhus, Denmark 9 Janssen-Cilag, Issy Les Moulineaux, France 10 Janssen-Cilag Ltd, High Wycombe, UK 11 Janssen-Cilag BV, Tilburg, Netherlands 12 St John's Institute of Dermatology, King's College, London, UK 13 Georg-August University, Hamburg, Germany Introduction & Objectives: Little evidence is available to guide physicians when transitioning patients with psoriasis directly from conventional to biologic therapy. We compared two methods of transitioning from methotrexate (MTX) to ustekinumab (UST), following inadequate MTX response. The efficacy of escalating UST dose in patients without an early response was examined. Materials & Methods: In this 52-week, randomised, open-label study, 490 patients with moderate to severe plaque psoriasis and inadequate MTX response, defined as Psoriasis Area Severity Index (PASI) score greater than or equal to10 after greater than or equal to 8 weeks of MTX (10-25mg/week), were randomised 1:1 to UST with either a) immediate cessation of MTX (Arm 1), or b) MTX gradually withdrawn over 4 weeks (Arm 85